Download PDF
The Journal of Hip Surgery
DOI: 10.1055/s-0043-1778088
Original Article

Trends in Opioid Use during Hospitalization following Revision Total Hip Arthroplasty from 2016 to 2021

Spencer A. Ward 
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
,
Emily M. Ronan 
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
,
Thomas H. Christensen
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
,
Thomas Bieganowski
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
,
Roy I. Davidovitch
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
,
William Macaulay
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
,
Ran Schwarzkopf
1   Department of Orthopedic Surgery, NYU Langone Health, New York, New York
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Though opioids can be very effective for postoperative pain management after revision total hip arthroplasty (rTHA), many physicians have made an effort to decrease usage of these medications by focusing on alternative pain management strategies to reduce opioid dependence and unwanted side effects. This study sought to investigate trends in opioid consumption during hospitalization following rTHA from 2016 to 2021. We retrospectively reviewed all patients who received rTHA from January 2016 to April 2021. Baseline demographic variables including age, gender, race, body mass index, and American Society of Anesthesiologists classification were recorded. Additional information including patient-reported outcome measures (PROMs), postoperative outcomes, dosage, and type of opioid medication prescribed postoperatively were also collected. Opioid dosage and type were converted to milligram morphine equivalents (MMEs) per day of hospitalization and compared across the 6 years studied. Linear regression as well as t-tests were utilized to determine significant trends in MME consumption over time. In total, 1,096 patients met inclusion and exclusion criteria. The greatest daily average opioid consumption per patient was in 2017 (61.6 ± 155.4 MME per day) and the lowest was in 2021 (31.8 ± 105.8 MME per day). Linear regression analysis detected a downward trend of 4.97 MME per day each year, though these results were not statistically significant (R 2: 0.444, p = 0.089). t-Test analysis, however, did reveal a significant decrease in opioid consumption in the postprotocol cohort (38.41 ± 90.5 vs. 52.18 ± 120.2; p = 0.034). There was a significant increase in preoperative Hip Disability and Osteoarthritis Outcome Score, Joint Replacement scores (p = 0.007) over time as well as a significant decrease in preoperative visual analog scale pain scores (p = 0.012). The results of this study show that opioid consumption in 2021 was lower than in 2016 and 2017. This result emphasizes the effectiveness of protocols limiting opioid usage during hospitalization following rTHA. Moreover, the relatively consistent patient-reported outcome scores over time demonstrate that this decrease in opioid consumption per year does not impact patient-reported outcomes and satisfaction.

Keywords

revision - arthroplasty - opioids - pain management


Publication History

Received: 04 October 2022

Accepted: 17 November 2023

Article published online:
19 January 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Knight SR, Aujla R, Biswas SP. Total hip arthroplasty - over 100 years of operative history. Orthop Rev (Pavia) 2011; 3 (02) e16
    PubMedGoogle Scholar
  • 2 Felson DT. Epidemiology of hip and knee osteoarthritis. Epidemiol Rev 1988; 10: 1-28
    CrossrefPubMedGoogle Scholar
  • 3 Bozic KJ, Kurtz SM, Lau E, Ong K, Vail TP, Berry DJ. The epidemiology of revision total hip arthroplasty in the United States. J Bone Joint Surg Am 2009; 91 (01) 128-133
    CrossrefPubMedGoogle Scholar
  • 4 Springer BD, Fehring TK, Griffin WL, Odum SM, Masonis JL. Why revision total hip arthroplasty fails. Clin Orthop Relat Res 2009; 467 (01) 166-173
    CrossrefPubMedGoogle Scholar
  • 5 Gaffney CJ, Pelt CE, Gililland JM, Peters CL. Perioperative pain management in hip and knee arthroplasty. Orthop Clin North Am 2017; 48 (04) 407-419
    CrossrefPubMedGoogle Scholar
  • 6 Højer Karlsen AP, Geisler A, Petersen PL, Mathiesen O, Dahl JB. Postoperative pain treatment after total hip arthroplasty: a systematic review. Pain 2015; 156 (01) 8-30
    CrossrefPubMedGoogle Scholar
  • 7 Khaw D, Bucknall T, Considine J. et al. Six-year trends in postoperative prescribing and use of multimodal analgesics following total hip and knee arthroplasty: a single-site observational study of pain management. Eur J Pain 2021; 25 (01) 107-121
    CrossrefPubMedGoogle Scholar
  • 8 Buvanendran A, Kroin JS, Tuman KJ. et al. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial. JAMA 2003; 290 (18) 2411-2418
    CrossrefPubMedGoogle Scholar
  • 9 Kukreja P, Avila A, Northern T, Dangle J, Kolli S, Kalagara H. A retrospective case series of Pericapsular Nerve Group (PENG) block for primary versus revision total hip arthroplasty analgesia. Cureus 2020; 12 (05) e8200
    PubMedGoogle Scholar
  • 10 Singh JA, Lewallen D. Age, gender, obesity, and depression are associated with patient-related pain and function outcome after revision total hip arthroplasty. Clin Rheumatol 2009; 28 (12) 1419-1430
    CrossrefPubMedGoogle Scholar
  • 11 Saleh KJ, Celebrezze M, Kassim R. et al. Functional outcome after revision hip arthroplasty: a metaanalysis. Clin Orthop Relat Res 2003; (416) 254-264
    CrossrefPubMedGoogle Scholar
  • 12 Tan TL, Rondon AJ, Wilt Z. et al. Understanding opioid use after total hip arthroplasty: a comprehensive analysis of a mandatory prescription drug monitoring program. J Am Acad Orthop Surg 2020; 28 (20) e917-e922
    CrossrefPubMedGoogle Scholar
  • 13 Ochalek TA, Cumpston KL, Wills BK, Gal TS, Moeller FG. Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic. JAMA 2020; 324 (16) 1673-1674
    CrossrefPubMedGoogle Scholar
  • 14 Slavova S, Rock P, Bush HM, Quesinberry D, Walsh SL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend 2020; 214: 108176
    CrossrefPubMedGoogle Scholar
  • 15 Stoicea N, Costa A, Periel L, Uribe A, Weaver T, Bergese SD. Current perspectives on the opioid crisis in the US healthcare system: a comprehensive literature review. Medicine (Baltimore) 2019; 98 (20) e15425
    CrossrefPubMedGoogle Scholar
  • 16 Brat GA, Agniel D, Beam A. et al. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. BMJ 2018; 360: j5790
    CrossrefPubMedGoogle Scholar
  • 17 Hill MV, Stucke RS, McMahon ML, Beeman JL, Barth Jr RJ. An educational intervention decreases opioid prescribing after general surgical operations. Ann Surg 2018; 267 (03) 468-472
    CrossrefPubMedGoogle Scholar
  • 18 Karam JA, Schwenk ES, Parvizi J. An update on multimodal pain management after total joint arthroplasty. J Bone Joint Surg Am 2021; 103 (17) 1652-1662
    CrossrefPubMedGoogle Scholar
  • 19 Parvizi J, Miller AG, Gandhi K. Multimodal pain management after total joint arthroplasty. J Bone Joint Surg Am 2011; 93 (11) 1075-1084
    CrossrefPubMedGoogle Scholar
  • 20 Kehlet H, Werner M, Perkins F. Balanced analgesia: what is it and what are its advantages in postoperative pain?. Drugs 1999; 58 (05) 793-797
    CrossrefPubMedGoogle Scholar
  • 21 Parvizi J, Bloomfield MR. Multimodal pain management in orthopedics: implications for joint arthroplasty surgery. Orthopedics 2013; 36 (2, Suppl): 7-14
    CrossrefPubMedGoogle Scholar
  • 22 Pepper AM, Mercuri JJ, Behery OA, Vigdorchik JM. Total hip and knee arthroplasty perioperative pain management: what should be in the cocktail. JBJS Rev 2018; 6 (12) e5
    CrossrefPubMedGoogle Scholar
  • 23 National Center for Injury Prevention and Control. CDC compilation of benzodiazepines, muscle relaxants, stimulants, zolpidem, and opioid analgesics with oral morphine milligram equivalent conversion factors. Centers for Disease Control and Prevention; ; June 4, 2021
    Google Scholar
  • 24 Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 2011; 63 (Suppl. 11) S240-S252
    CrossrefPubMedGoogle Scholar
  • 25 Ip HY, Abrishami A, Peng PW, Wong J, Chung F. Predictors of postoperative pain and analgesic consumption: a qualitative systematic review. Anesthesiology 2009; 111 (03) 657-677
    CrossrefPubMedGoogle Scholar
  • 26 Quinlan J, Rann S, Bastable R, Levy N. Perioperative opioid use and misuse. Clin Med (Lond) 2019; 19 (06) 441-445
    CrossrefPubMedGoogle Scholar
  • 27 Dwyer MK, Tumpowsky CM, Hiltz NL, Lee J, Healy WL, Bedair HS. Characterization of post-operative opioid use following total joint arthroplasty. J Arthroplasty 2018; 33 (03) 668-672
    CrossrefPubMedGoogle Scholar
  • 28 Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med 2011; 12 (05) 747-754
    CrossrefPubMedGoogle Scholar
  • 29 Reid DBC, Shah KN, Shapiro BH, Ruddell JH, Akelman E, Daniels AH. Mandatory prescription limits and opioid utilization following orthopaedic surgery. J Bone Joint Surg Am 2019; 101 (10) e43
    CrossrefPubMedGoogle Scholar
  • 30 Reid DBC, Shapiro B, Shah KN. et al. Has a prescription-limiting law in rhode island helped to reduce opioid use after total joint arthroplasty?. Clin Orthop Relat Res 2020; 478 (02) 205-215
    CrossrefPubMedGoogle Scholar
  • 31 Wakeman SE, Green TC, Rich J. An overdose surge will compound the COVID-19 pandemic if urgent action is not taken. Nat Med 2020; 26 (06) 819-820
    CrossrefPubMedGoogle Scholar
  • 32 Wainwright JJ, Mikre M, Whitley P. et al. Analysis of drug test results before and after the US declaration of a national emergency concerning the COVID-19 outbreak. JAMA 2020; 324 (16) 1674-1677
    CrossrefPubMedGoogle Scholar
  • 33 Randall DJ, Vanood A, Jee Y, Moore DD. National and state level opioid-restricting legislation in total joint arthroplasty: a systematic review. J Arthroplasty 2022; 37 (01) 176-185
    CrossrefPubMedGoogle Scholar
  • 34 Wilson JM, Farley KX, Erens GA, Bradbury TL, Guild III GN. Preoperative opioid use is a risk factor for complication following revision total hip arthroplasty. Hip Int 2022; 32 (03) 363-370
    CrossrefPubMedGoogle Scholar
  • 35 Pivec R, Issa K, Naziri Q, Kapadia BH, Bonutti PM, Mont MA. Opioid use prior to total hip arthroplasty leads to worse clinical outcomes. Int Orthop 2014; 38 (06) 1159-1165
    CrossrefPubMedGoogle Scholar
  • 36 Smith E, Klemt C, Sabeh K, Tirumala V, Kwon YM. Patient-reported outcomes associated with preoperative opioid use in revision total hip arthroplasty: a propensity score-matched cohort study. J Am Acad Orthop Surg 2021; 29 (07) e330-e336
    CrossrefPubMedGoogle Scholar